MARKER THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
MARKER THERAPEUTICS, INC. (MRKR) reported Capital Expenditures Incurred but Not yet Paid of $141.98 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-03-26
- MARKER THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $141.98K, a 93.90% decline year-over-year.
- MARKER THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was -$24.69K, a 101.18% decline year-over-year.
- MARKER THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $66.17K.
- MARKER THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was -$2.31M.
- MARKER THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $57.61K, a 97.33% decline from fiscal 2021.
- MARKER THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $2.16M, a 83.07% increase from fiscal 2020.
- MARKER THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2020 was $1.18M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2023-03-31 | $141.98K 10-Q · filed 2023-05-15 | $117.29K derived: sum of 2 quarters · filed 2024-03-26 | $183.46K derived: sum of 3 quarters · filed 2024-03-26 | -$2.13M derived: sum of 4 quarters · filed 2024-03-26 |
| 2022-12-31 | -$24.69K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $41.48K derived: sum of 2 quarters · filed 2024-03-26 | -$2.27M derived: sum of 3 quarters · filed 2024-03-26 | $57.61K 10-K · filed 2024-03-26 |
| 2022-09-30 | $66.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$2.25M derived: sum of 2 quarters · filed 2022-11-10 | $82.30K 10-Q · filed 2022-11-10 | $2.17M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-06-30 | -$2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $16.13K 10-Q · filed 2022-08-11 | $2.11M derived: sum of 3 quarters · filed 2023-05-15 | $2.02M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-03-31 | $2.33M 10-Q · filed 2023-05-15 | $4.42M derived: sum of 2 quarters · filed 2023-05-15 | $4.33M derived: sum of 3 quarters · filed 2023-05-15 | $4.27M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $2.00M derived: sum of 2 quarters · filed 2023-03-22 | $1.94M derived: sum of 3 quarters · filed 2023-03-22 | $2.16M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$89.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$149.77K derived: sum of 2 quarters · filed 2022-11-10 | $70.40K 10-Q · filed 2022-11-10 | -$644.22K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$60.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $159.98K 10-Q · filed 2022-08-11 | -$554.64K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $220.17K 10-Q · filed 2022-05-13 | -$494.45K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$714.62K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.18M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $1.89M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |